anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Classic hereditary hemochromatosis (HH) is an autosomal recessive iron-overload disorder resulting from loss-of-function mutations of the HFE gene. Patients with HH exhibit excessive hepatic iron accumulation that predisposes these patients to liver disease, including the risk for developing liver cancer. Chronic iron overload also poses a risk for the development of metabolic disorders such as obesity, type 2 diabetes, and insulin resistance. We hypothesized that liraglutide, GLP1 receptor agonist, alters iron metabolism while also reducing body weight and glucose tolerance in a mouse model of HH (global HFE knockout, HFE KO) and diet-induced obesity and glucose intolerance. The total body HFE KO and wild-type control mice were fed high-fat diet for 8 weeks. Mice were subdivided into liraglutide and vehicle-treated groups and received daily subcutaneous administration of the respective treatment once daily for 18 weeks. Liraglutide improved glucose tolerance and hepatic lipid markers and reduced body weight in a mouse model of HH, the HFE KO mouse, similar to wild-type controls. Importantly, our data show that liraglutide alters iron metabolism in HFE KO mice, leading to decreased circulating and stored iron levels in HFE KO mice. These observations highlight the potential that GLP1 receptor agonist could be used to reduce iron overload in addition to reducing body weight and improving glucose regulation in HH patients.
Abstract The lnvention relates to dibenzazepine derivatives of formula (I)                 (I) and the prsparation and use thereof. In formula (I), R1, R2, R3 and R4 represent hydrogen or halogen, or an alkyl or alkoxy group, each with 1 to 6 carbon atoms, R5   represents hydrogen, alkyl with 1 to 6 carbon atoms or alkenyl with 3 to 6 carbon atoms, R6    represents alkyl with 1 to 6 carbon atoms, alkenyl with 3 to 6 carbon atoms, a phenyl group optionally substituted by halogen, alkyl or alkoxy groups, or an optionally substituted phenylalkyl group witb the partial formula    , wherein R1' and R2' may have the same meanings as. R1 and R2 but need not be identical to them, and n represents one of the integers from 0 to 4, X     represents O, S or CH2, and the dotted line indicates the presence of either a single or a double bond.      Compounds which have an asymmetric carbon atom may occur as racemates, as pure enantiomers or as mixtures containing differing proportions of the enantiomers.  The compounds may occur in the form of the free bases or the acid addition salts.      The new compounds have an anti-allergic, anti-histaminic and anti-serotonin activity and may therefore be used as medicaments.
The present invention relates generally to vesicles such as liposomes, colloidosomes, and polymersomes, as well as techniques for making and using such vesicles. In some cases, the vesicles may be at least partially biocompatible and/or biodegradable. The vesicles may be formed, according to one aspect, by forming a multiple emulsion comprising a first droplet surrounded by a second droplet, which in turn is surrounded by a third fluid, where the second droplet comprises lipids and/or polymers, and removing fluid from the second droplet, e.g., through evaporation or diffusion, until a vesicle is formed. In certain aspects, the size of the vesicle may be controlled, e.g., through osmolarity, and in certain embodiments, the vesicle may be ruptured through a change in osmolarity. In some cases, the vesicle may contain other species, such as fluorescent molecules, microparticles, pharmaceutical agents, etc., which may be released upon rupture. Yet other aspects of the invention are generally directed to methods of making such vesicles, kits involving such vesicles, or the like.
An extended wear electrocardiography patch is provided. An integrated flexible circuit includes a single piece of material and has an upper end and a lower end opposite the upper end. A mirror image of the upper end extends from at least a portion of one side of the upper end and folds over the upper end. One circuit trace is positioned on the upper end and one circuit trace is positioned on the lower end. Electrical pads are located on a contact surface of the upper end and on an outward facing surface of the mirror image of the upper end. An electrocardiographic electrode is positioned on the contact surface of the upper end and another electrocardiographic electrode is positioned on a contact surface of the lower end. A battery is directly adhered to the outward facing surface of the mirror image of the upper end.
The present disclosure provides a film for application to the living body, which is advantageous for bonding to the living body, while containing a regenerated cellulose. A film (10a) for application to the living body according to the present disclosure is a self-supporting film which contains a regenerated cellulose, while having a thickness of from 20 nm to 2,000 nm. This film (10a) for application to the living body has a first main surface (11) and a second main surface (12) which is on the reverse side of the first main surface 11. This film (10a) for application to the living body has a planer first region (13) and a planer second region (14). The first region (13) is in contact with the first main surface (11) in the thickness direction of the film (10a) for application to the living body, while being positioned at a distance from the second main surface (12). The second region (14) is positioned between the first region (13) and the second main surface (12) in the thickness direction of the film (10a) for application to the living body. The bulk density of the regenerated cellulose in the second region (14) is higher than the bulk density of the regenerated cellulose in the first region (13).
Bydureon® (exenatide) is supplied as powder and solvent for prolonged release injection (once-weekly). Bydureon® is delivered in a carton containing four pens. Each single-dose, dual-chamber pen contains 0.65 ml of diluent and 2 mg of exenatide, which are isolated until mixed by the person administering the drug. Needles are supplied with the pen.
PURPOSE OF REVIEW: Obesity is one of the most common pediatric chronic conditions in the United States, affecting approximately 20% of American youth and is more common amongst Black, Latino, and Indigenous and low socioeconomic populations. The condition places children and adolescents at increased risk of physical and mental health conditions partly mediated by the weight bias and stigmatization experienced during the potentially vulnerable periods of childhood and adolescence.
RECENT FINDINGS: Weight bias and the resulting stigma are pervasive in society. Children have been shown to internalize this bias and its devaluation, which have been shown to contribute to worsening metabolic and mental health outcomes independently. Studies suggest weight stigmatization more adversely affects Black, Latino, and Indigenous children, suggesting the potential for adverse synergistic effects of these historical biases on such youth.
SUMMARY: Addressing childhood obesity successfully across all racial, ethnic, and socioeconomic lines requires addressing weight bias and stigma. Steps toward this end include collaborative efforts to promote cross-cultural competence and upstander bias education and training for those who care for children, person-centered communication, and a culture of inclusivity across governmental, healthcare, educational, entertainment, and advertising sectors.
This treatment arm will receive saline solution. The dose will be given at a single time point within 4 hours of randomization. The dose will be administered through three subcutaneous injections, each in a different quadrant of the abdomen.
Breast cancer is the most common type of cancer among women. The study of the mechanisms of metastasis, the main cause of death from breast cancer, as well as the search for new markers for early diagnosis and prognosis of breast cancer, is an extremely topical issue. New perspectives in the diagnosis and treatment of breast cancer are opened by the mechanisms of gene regulation involving non-coding RNAs, in particular, long non-coding RNAs (lncRNAs). In this work, we analyzed the methylation levels of seven lncRNA genes (MEG3, SEMA3B-AS1, HAND2-AS1, KCNK15-AS1, ZNF667-AS1, MAGI2-AS3, and PLUT) by quantitative methyl-specific PCR on a set of 79 paired (tumor/normal) samples of breast cancer. Hypermethylation of all seven lncRNA genes was revealed, and hypermethylation of HAND2-AS1, KCNK15-AS1, MAGI2-AS3, and PLUT was detected in breast cancer for the first time. It was found that the level of meth ylation of the studied lncRNA genes correlated statistically significantly with the stage of the tumor process, the size of the tumor, and the presence of metastases in the lymph nodes. Thus, methylation of the seven studied lncRNA genes is associated with the development and progression of breast cancer, and these genes can be useful as potential markers in the diagnosis and prognosis of breast cancer.
The invention provides promote digestion and relieve stasis Chinese traditional medicine preparation used for animals and the preparation method thereof, at the same time, the invention also provides the quality control method of the powder medicine of the invention. The animal promote digestion and relieve stasis Chinese traditional medicine preparation of the invention is formed by mixing and preparing areca, kaladana, euphorbia, astragalus root, Radix Scutellariae, rhubarb and talcum. The medical raw materials are smashed, mixed evenly, and then bagged, then the powder medicine of the invention is obtained, and also the medical raw materials can be extracted to be prepared into a variety of routine preparation types. The animal promote digestion and relieve stasis Chinese traditional medicine preparation of the invention is prepared by common Chinese herbal medicine as the raw materials, the invention can effectively treat the livestock digestive tract diseases of forestomach relaxation, rumen food retention, etc., and has a certain curative effect on three stomach impaction. The manufacturing process of the preparation of the invention is simple, and the cost of production is low. At the same time, the invention also provides the quality control method of the powder medicine of the animal promote digestion and relieve stasis Chinese traditional medicine preparation for the production of the powder medicine of the invention to provide the corresponding standards.
Overdoses of nizatidine have been reported rarely. The following is provided to serve as a guide should such an overdose be encountered.

Signs and Symptoms – There is little clinical experience with overdosage of nizatidine in humans. Test animals that received large doses of nizatidine have exhibited cholinergic-type effects, including lacrimation, salivation, emesis, miosis, and diarrhea. Single oral doses of 800 mg/kg in dogs and of 1,200 mg/kg in monkeys were not lethal. Intravenous median lethal doses in the rat and mouse were 301 mg/kg and 232 mg/kg respectively.

Treatment – To obtain up-to-date information about the treatment of overdose, a good resource is your certified Regional Poison Control Center. Telephone numbers of certified poison control centers are listed in the Physicians' Desk Reference (PDR). In managing overdosage, consider the possibility of multiple drug overdoses, interaction among drugs, and unusual drug kinetics in your patient.

If overdosage occurs, use of activated charcoal, emesis, or lavage should be considered along with clinical monitoring and supportive therapy. The ability of hemodialysis to remove nizatidine from the body has not been conclusively demonstrated; however, due to its large volume of distribution, nizatidine is not expected to be efficiently removed from the body by this method.
The invention relates to the field of traditional Chinese medicine application, and particularly discloses a development assistance traditional Chinese medicine used for B ultrasonography. The traditional Chinese medicine is prepared from raw materials including Loropetalum chinensis (R. Br.) Oliv leaves, pine pollen, Herba Clinopodii, girald pteroxygonum roots, lotus rhizome nodes, Melastoma dodecandrum Lour. roots, Agrimonia pilosa Ldb., bletilla roots, myrrh, curcuma longa, Sargentodoxa cuneata, olibanum, dry roots of Zanthor Mulum nitidum(Roxb.)DC., rhizome corydalis decumbentis, Corydalis yanhusuo W. T. Wang ex Z. Y. Su et C. Y. Wu, common camptotheca fruit, cortex albiziae, Valeriana officinalis L., seeds of Platycladus orientalis(L.)Franco, pearl and pseudo-ginseng according to a certain weight ratio. The traditional Chinese medicine is low in manufacturing cost, convenient to use, safe, free of toxic and side effects, and capable of increasing the excellent development ratio and improving detection accuracy, more gastrointestinal diseases can be examined through B ultrasonography, powerful foundation is provided for clinical diagnosis, and the preparation process is simple and practical.
This is a prospective, non-interventional, observational, multi-centre, real-world study designed to monitor the general condition, treatment pattern and prognosis of patients with GCLM. GCLM patients were divided into 3 types: Type I (resectable type), Type II (potentially resectable type), Type III (unresectable type). The patients' general information, past medical history, imaging results, laboratory tests, surgical and systemic therapy details will be recorded and analysed. The 2-year overall survival (OS) will be recorded as the primary endpoint. The different therapies (surgery, chemotherapy and immunotherapy) of GCLM, the effects of different therapies on prognosis including OS of type I, II and III; R0 resection rate and diease free survival (DFS) of type I; successful conversion rate and R0 resection rate and events free survival (EFS) of type II will be recorded as secondary endpoints.

This study involving human participants were reviewed and approved by the Ethics Committee of Chinese PLA General Hospital (No.S2023-724-02) and will be conducted according to the guidelines of the Declaration of Helsinki. Study findings will be disseminated through international peer-reviewed journal articles as well as public, academic presentations at national and international conferences.
PURPOSE: The purpose of this study is to compare the opioid requirement and pain intensity after surgeries of mandibular fractures with administration of dexmedetomidine by two approaches of infusion and single bolus.
METHODS: In this double-blind clinical trial, the participants were randomized and matched in terms of age and gender in two groups (infusion and bolus). In both groups, the amount of narcotic used, hemodynamic indices, oxygen saturation, and pain intensity were collected based on the ten-point Visual Analogue Scale (VAS) at 7 time points for 24 h. SPSS version 24 software was used for data analysis. A significance level of less than 5% was considered.
RESULTS: A total of 40 patients were included in the study. There was no significant difference between the two groups in terms of gender, age, ASA class, and duration of surgery (P>0.05). There was no significant difference between the two groups in terms of nausea and vomiting and subsequently receiving anti-nausea medication (P>0.05). The need for opioid consumption after surgery was not different in two groups (P>0.05). Infusion of dexmedetomidine reduced postoperative pain more rapidly than its single bolus dose (P<0.05). However, over time, there was no significant difference between the two groups in terms of changes in oxygen saturation variables (P>0.05). Homodynamic indices including heart rate, systolic blood pressure, and diastolic blood pressure in the bolus group were significantly lower than the infusion group (P<0.05).
CONCLUSION: Administration of dexmedetomidine in the form of infusion can reduce postoperative pain better than bolus injection, with less probability of hypotension and bradycardia.
Provided are a viral vector-based RNA delivery system and a use thereof. The RNA delivery system comprises a viral vector. The viral vector carries an RNA fragment needing to be delivered, and can be enriched in organ tissues of a host. In the host organ tissues, the viral vector can endogenously and spontaneously form a composite structure containing the RNA fragment. The composite structure can enter and bind to target tissues, and feed the RNA fragment into the target tissues. The viral vector has a targeting tag. The composite structure is an exosome. The viral vector RNA delivery system is safe and reliable, and has good druggability and high universality.
In group 3, in addition to the active ankle pumping exercise for the operative limb, the patients were reminded to exercise at specific time points with a vocal alarm and vibration through a wrist watch during the hospitalization period and at home after discharge. The watch was continuously used until the 14th day when the patients returned to the hospital for examination.
This arm will be treated with continuous subcutaneous infusion of apomorphine. The infusion will start with 1 mg/hr during the waking day (approximately 16 hours). The flow rate will be adjusted on a weekly basis, and may be increased with 0.5 to 1.0 mg/hr per discretion of the investigator, aiming at the disappearance of visual hallucinations. The duration of treatment is 4 weeks.
A method of opioid replacement is described which involves modulating the expression of dopaminergic genes (such as DRD2), as indicative of substance use disorders in individuals utilizing opioids and desirous of opioid replacement. Opioid replacement can involve a decrease in opioid seeking behavior of the subject, who may require pain management. A cannabinoid formulation is described comprising primarily cannabichromene (CBC) together with an excipient. A method is described for detecting the correlation between CBC treatment and downregulation of biomarkers of DRD2 gene expression. An effective non-psychoactive pain management therapy for opioid replacement is provided, as validated based on the gene expression profile of patients, where patient response to cannabichromene treatment can be predicted by such biomarkers. Such a therapy has the potential to reverse the transcriptional profile of DRD2 through tapering of opioid-induced upregulation, and/or through the potential downregulation of DRD2 expression.
In the United States, 10% to 15% of adults are affected by gallstones, and cholesterol gallstones are the most prevalent subtype. Risk factors for developing gallstone disease include female sex; older age; certain medications; and having type 2 diabetes mellitus, nonalcoholic fatty liver disease, obesity, rapid weight loss, or hemolytic anemia. Nearly 80% of gallstones are found incidentally and remain asymptomatic. When symptomatic, gallstone disease usually presents as sudden onset right upper quadrant or epigastric abdominal pain. Common complications of gallstones include cholecystitis, choledocholithiasis, gallstone pancreatitis, and ascending cholangitis. The Murphy sign is a specific physical examination finding for acute cholecystitis. Ultrasonography is the initial imaging choice for detecting gallstones and acute cholecystitis. A hepatobiliary iminodiacetic acid (HIDA) scan can be used to evaluate for cholecystitis in patients with negative or equivocal ultrasound findings. Magnetic resonance cholangiopancreatography (MRCP) is an accurate, noninvasive diagnostic test to identify choledocholithiasis, certain malignancies, and biliary obstruction. Nonsteroidal anti-inflammatory drugs are safe and effective in treating pain from acute cholecystitis and biliary colic. Laparoscopic cholecystectomy is the treatment of choice for most patients with biliary colic or acute cholecystitis. Ursodeoxycholic acid and chenodeoxycholic acid should not routinely be used to treat gallstone disease, but they can be used as a nonsurgical alternative for certain patients. Postcholecystectomy syndrome is a potential postoperative complication that presents with abdominal pain, bloating, and diarrhea. (Am Fam Physician. 2024;109(6):518-524.
OBJECTIVE: To investigate the effects of combining traditional Chinese medicine acupoint sticking with sea salt hot compress on pain relief and promoting physical and mental comfort in infertile women undergoing Hysterosalpingo contrast sonography (HyCoSy).
METHODS: Infertile women admitted to Zhujiang Hospital of Southern Medical University from October 2021 to December 2022 were selected and 150 of them were selected by random number table method as the main subjects of the study and divided into three groups. The control group received psychological soothing and music therapy. The hot compress group received a sea salt package hot compress at temperatures of 50-65°C in addition to psychological and music soothing. The combined group received an acupoint application of traditional Chinese medicine along with the hot compress and psychological soothing. Pain levels, assessed using the Numeric Rating Scale (NRS), were recorded at different stages of the HyCoSy procedure: cervical dilatation (T0), balloon intubation (T1), contrast medium injection (T2), 10 minutes after examination (T3), 30 minutes after examination (T4), 24 hours after examination (T5), 48 hours after examination (T6), and 1 week after examination (T7).Stacey salpingography adverse reaction grading method: Adverse reactions were evaluated using the grading method for adverse reactions in salpingography designed by Stacey, and adverse reactions were classified into 0 to 4 levels. Stacey grading was used to evaluate pain severity, and adverse reactions of the vagus nerve, anxiety status, and test comfort were also compared among the three groups.
RESULTS: Statistically significant differences in NRS scores were observed among the three groups of patients at various stages of the HyCoSy procedure (T0-T5) (P = .001, P = .001, P = .001, P = .001, P = .012,). The combined group showed a higher proportion of grade 1-2 pain (96%) compared to the control group (83%) and the hot compress group (90%), while the proportion of grade 3 pain (4%) was lower than that in the control group (17%) and the hot compress group (10%) (P < .001). There were no significant differences in anxiety scores before and 1 week after examination (P= .273, P = 1.000, P = .779). The Kolcaba comfort scores were significantly higher in the combined group (67.54±7.58) and the hot compress group (65.02±8.12) compared to the control group (58.96±7.53) (P < .001,). No complications, scalds, or severe skin allergies were reported in any of the three groups during the one-week follow-up.
CONCLUSIONS: The combination of acupoint application with hot compress during HyCoSy resulted in reduced pain levels and improved physical and mental comfort in infertile women. This simple and safe approach can be effectively utilized in clinical practice to enhance the patient experience during the procedure.